艾迪注射液联合化疗药物治疗晚期大肠癌的临床研究  

Clinical Research of Combined Aidi Injection with Chemotherapy on Advanced Colorectal Cancer

作　　者：张荣生[1] 李永萍[1] 张静[1] 何丽娟[1] 李树明[1] 

机构地区：[1]大理学院附属医院内科,云南大理671000

出　　处：《大理学院学报（综合版）》2008年第12期43-45,共3页Journal of Dali University

摘　　要：目的:观察艾迪注射液联合化疗药物治疗晚期大肠癌的临床疗效。方法:选择晚期大肠癌患者62例,分为艾迪注射液联合化疗组30例(治疗组)及单纯化疗组32例(对照组),完成2个治疗周期后进行疗效评价。结果:治疗组有效率为43.3%,对照组为40.6%,两组比较无显著差异(P>0.05);治疗组在生活质量等方面疗效明显优于对照组(P<0.05);治疗组毒副反应发生率低于对照组(P<0.05)。结论:艾迪注射液联合化疗对治疗晚期大肠癌有较好疗效,能有效改善临床症状,减轻化疗药物的毒副反应,提高生活质量,值得推广。Objective：To evaluate the efficacy of combined Aidi injection with chemotherapy for the treatment of advanced colorectal cancers. Methods： Sixty-two cases with advanced colorectal cancer were divided into two groups. Thirty patients of test group were treated with combination of Aidi injection and chemotherapy, and Thirty-two patients of the control group only received chemotherapy. The curative effects were evaluated after 2 circles. Results： The total efficiency rates in two groups were 43.3% and 40.6%（P〉0.05）.The life quality of patients in test group was superior to the patients in control group （P〈0.05）. The incidence rates of the side effect in test group were lower than those of control group （P〈0.05）. Conclusion： Combined Aidi injection and chemotherapy can improve the curative effect of advanced colorectal cancer and the patients quality of life.

关 键 词：艾迪注射液 化疗 大肠癌 

分 类 号：R979.1[医药卫生—药品]